China Isotope & Radiation Corporation (CIRC) aksje
1763.HK
CIRC
Market Cap
$5,693,773,312
Om China Isotope & Radiation Corporation (CIRC) aksje
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of nuclides, diagnostic, and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. The company operates through five segments: Nuclear Medicines; Radioactive Source Products; Irradiation; Nuclear Medical Equipment and Related Services; and Other Businesses. The Nuclear Medicines segment engages in research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals, urea breath test diagnostic kits, test analyzers, and other products. The Radioactive Source Products segment sells medical and industrial radioactive sources products and related technical services. The Irradiation segment offers irradiation services to manufacturers of medical devices, pharmaceuticals, cosmetics, and food for sterilization, and provides design, manufacturing, and installation of gamma ray irradiation facilities and related technical services. The Nuclear Medical Equipment and Related Services segment sells nuclear medical equipment and provides related maintenance services. The Other Businesses segment provides trade services for nuclear technology industry applications, medical product applications, technical services, and sales of medical devices. This segment also offers independent clinical laboratory services for nuclear technology industry applications and medical product applications; and provides radioactive sources, medical nuclides, imported radiopharmaceuticals, nuclear instruments and devices, medical equipment and other products. The company was incorporated in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation operates as a subsidiary of China National Nuclear Corporation.
Selskapsinformasjon
Beijing, China
Analytikernes aksjeanbefalinger
Denne oversikten gir et raskt innblikk i hvordan analytikere vurderer aksjens potensial basert på deres siste analyser og kursmål.